Jubilant Ingrevia Limited — Updates, 31-07-2025: Press Release

Jubilant Ingrevia reported strong financial results for the quarter. Revenue was 1,038 Cr (up 1% YoY), EBITDA 153 Cr (up 29% YoY), and Profit After Tax 75 Cr (up 54% YoY). Specialty Chemicals led growth with 11% YoY revenue and 52% YoY EBITDA. The pharma CDMO pipeline doubled, and a $300 million agro contract is on track for early next year. The company is driving Lean 2.0 cost efficiency targeting 100 Cr+ annual savings and expanding capacity. US and ROW markets showed strong revenue growth.